Evolving Treatment Strategies in the Management of Metastatic Melanoma: Optimizing Immunotherapy Approaches for Improved Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2022, to August 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp

Melanoma is the most serious type of skin cancer. It occurs in skins cells called melanocytes, and while it is predominantly found in the skin, it can occur in any area of the body that contains melanocytes. Melanoma will be found in approximately 106,110 people in the United States in 2021 according to the
National Cancer Institute. While it is the least common amongst skin cancers, it is by far the deadliest,
with 7,180 people expected to die in 2021. Both of those numbers have been rising in recent years. In the
early stages of melanoma, prognosis is usually good for patients, but when the melanoma becomes metastatic and spreads to other areas of the body, prognosis is especially poor. Fortunately for patients
with metastatic melanoma, and the physicians that treat them, significant progress has been made in the
treatment of this deadly disease over the past 10 years, especially in the area of immunotherapies. With
several new therapy options and indications recently approved for patients, including as an adjuvant
treatment in melanoma, it is critical to educate medical directors, practicing physicians, nurses and other healthcare professionals on the recent updates in treatment options and guideline recommendations.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of metastatic melanoma, including factors that contribute to poor prognosis and increased costs

  • Differentiate current and emerging treatments for patients with metastatic melanoma

  • Assess recent and emerging clinical data on safety and efficacy of novel immunotherapeutic approaches for treating patients with melanoma

  • Explore strategies to properly identify patients for neoadjuvant and adjuvant systemic therapies in resectable melanoma

  • Identify immune-related adverse events and appropriate management strategies associated with immunotherapy treatment of melanoma

  • Apply current evidence to individualize clinical and managed care decision-making for patients with metastatic melanoma


Faculty: Ragini Kudchadkar, MD
Associate Professor, Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Kudchadkar has served on an advisory board for BMS, DelCath, Eisai, Immunocore, InstilBio, Merck, Pfizer, and Regeneron. She has received grant/research support from BMS, Merck, and Regeneron. Her presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue